Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8TDR0
UPID:
MIPT3_HUMAN
Alternative names:
Interleukin-13 receptor alpha 1-binding protein 1; Intraflagellar transport protein 54 homolog; Microtubule-interacting protein associated with TRAF3
Alternative UPACC:
Q8TDR0; Q6PCT1; Q7L8N9; Q9NRD6; Q9Y4Q1
Background:
TRAF3-interacting protein 1, also known as Interleukin-13 receptor alpha 1-binding protein 1, plays a pivotal role in inhibiting IL13 signaling, crucial for suppressing IL13-induced STAT6 phosphorylation, transcriptional activity, and DNA-binding. It is instrumental in kidney development, epithelial morphogenesis, and microtubule cytoskeleton organization, acting as a negative regulator of microtubule stability through the control of MAP4 levels.
Therapeutic significance:
Linked to Senior-Loken syndrome 9, a renal-retinal disorder, TRAF3-interacting protein 1's involvement in disease pathways underscores its potential as a target for therapeutic intervention. Understanding its role could pave the way for novel treatments for this syndrome.